Molecules of the Month

May 2022

A fat-tissue-targeting clinical candidate, a first-in-class Ph. III molecule that inhibits its target by covalently modifying the target’s substrate, and a fourth-generation glucokinase activator are some examples in Drug Hunter’s May 2022 edition of Molecules of the Month. In this month’s slide deck, you’ll find a molecule that had mitigated QTc prolongation over a prior molecule while hERG inhibition stayed constant, why reversible MAGL inhibition is being pursued, and much more, including:

  • Industry context behind the molecules, target, and clinical applications

  • Biological rationale for drugging the targets

  • Mechanisms of action for the drugs

  • Hit-finding and lead optimization strategies and tactics used

  • Highlights from the binding modes and PDB codes where relevant

  • Interesting aspects from the preclinical and clinical pharmacology

  • Relevant patents and company history

Thanks to reviewers Ron Li, Julien Lefranc, Bryan McKibben, and Romyr Dominique for their nominations and commentary this month.

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.